Linagliptin and Digoxin Drug-Drug Interaction Study

Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve in plasma at steady state over a uniform dosing interval for digoxin at 144 hours, Maximum measured concentration in plasma at steady state for digoxin at 144 hours and 1 more. Started Jun 2008; status: completed.